GHK-Cu Side Effects: What the Cosmetic and Wound-Healing Evidence Says
GHK-Cu is a copper-binding tripeptide marketed in cosmetics for skin appearance, hair, and wound-healing research. It is not approved by the FDA or TGA as a drug for therapeutic claims. Most published safety data come from topical formulations; injected use is not regulator-supported.
GHK-Cu is not FDA-approved and lacks controlled human safety data. Not FDA-approved as a drug. Used as a cosmetic ingredient in topicals. Injected use is not supported by regulators and is not characterised by controlled human trials. This page summarises the published literature and regulator positions. It is not medical advice.
Key Takeaways
- GHK-Cu is a copper-binding tripeptide. It is not FDA-approved as a drug; it appears in cosmetic topicals.
- Most published safety evidence is from topical cosmetic use, not injection. Injected use is not supported by controlled human trials.
- Theoretical concerns with non-pharmaceutical injected GHK-Cu include copper exposure, immunogenicity, impurity-related effects, and injection-site infection.
- Speak to your doctor or pharmacist before using any compounded peptide. This page summarises peer-reviewed literature for general information only.
What is GHK-Cu, and what is it marketed for?
Glycyl-L-histidyl-L-lysine copper complex. GHK-Cu is a tripeptide (glycyl-L-histidyl-L-lysine) that chelates copper. Pickart and colleagues described copper transport activity and effects on extracellular matrix proteins in cell-culture and animal models. Mechanisms reported in the peer-reviewed literature include modulation of collagen, glycosaminoglycan, and elastin production, and effects on antioxidant and inflammatory pathways. Most published evidence is preclinical or topical-cosmetic; injected human data are very limited.
What side effects and safety concerns have been reported?
The summary below draws from the published literature and regulator statements. Severity classification follows the source documents.
| Concern | What has been reported | Source |
|---|---|---|
| Skin reactions to topical | Contact dermatitis, irritation, redness | Reported with copper-peptide topicals |
| Copper exposure (injection) | Theoretical risk of systemic copper accumulation with repeated injection of non-pharmaceutical-grade product | Copper homeostasis in humans is tightly regulated; injected exposure outside trials is uncharacterised |
| Injection-site infection (research-grade) | Pain, warmth, swelling, abscess if non-sterile | Compounded or research-grade products are not pharmaceutical-grade |
| Long-term effects | Not characterised in controlled human studies of injected GHK-Cu | No long-term human safety trials of injected GHK-Cu published |
| Impurity exposure | Effects of non-listed contaminants in research-grade products | Compounded peptides have variable purity |
Taking GHK-Cu alongside prescription medicines?
Allmeds scans interactions across your full medication list. Free for individuals.
Common Questions About GHK-Cu
No. GHK-Cu is not FDA-approved as a drug for any therapeutic claim. It appears as an ingredient in cosmetic topicals, which are regulated separately under cosmetic rules. Injected forms sold through compounding pharmacies or research-grade suppliers are not FDA-approved products.
For topical cosmetic use, contact dermatitis and skin irritation have been reported. For injected use, controlled human safety data are very limited. Most published evidence is preclinical, in cell culture or animal models. Speak to your prescriber before considering injected use.
Peer-reviewed reviews by Pickart and colleagues describe effects on collagen, glycosaminoglycan, and elastin production in cell-culture and animal models, as well as effects on antioxidant and inflammatory pathways. The strength of the evidence for human therapeutic claims is limited and the published work is overwhelmingly preclinical or topical-cosmetic.
Theoretical concerns reported in regulatory and pharmacy-grade peptide reviews include the absence of controlled human safety data, copper exposure with repeated injections, immunogenicity, impurity-related effects in research-grade products, and infection risk from non-sterile injection. These are reasons to discuss any planned use with a clinician.
Yes. Clinicians should know about all topical or injected substances you use, especially before surgery, pregnancy, cancer treatment, or any change to prescription medicines.
References
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. Source.
- U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Source.
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. Source.
- Therapeutic Goods Administration (Australia). Cosmetics regulation summary. Source.